Centre studying take-over of foreign drug firms

The web searches yielded limited whitelisted results, so I will ground this note primarily in the article content (The Hindu archive, Tier 4) supplemented by verifiable contextual facts. The article is a 1976 reprint from The Hindu's archives — the "today's paper" is the January 23, 1976 edition.

Centre Studying Take-Over of Foreign Drug Firms

Hathi Committee Report & India's Pharmaceutical Policy Debate

1. At a Glance

• The Hathi Committee (1974–75) recommended nationalisation/takeover of multinational corporations (MNCs) operating in India's pharmaceutical sector, triggering a prolonged policy debate [S1].
• On January 22, 1976, the Minister of Chemical and Fertilizers, P.C. Sethi, told the Lok Sabha that the takeover question was "under the consideration of the Government" [S1].
• UPSC relevance: this topic anchors GS-III (industry policy, public vs. private sector debate) and GS-II (parliamentary oversight, committee reports); it also surfaces in essays on India's self-reliance narrative.
• The episode is an early case study of India's post-independence tension between essential medicine access, FDI regulation, and technology dependence — a debate that persists today.

2. Why in the News

• January 22–23, 1976 (original trigger): Lok Sabha debate initiated by CPI members Ramavtar Shastri and Hiren Mukherjee on the Hathi Commission report; multiple members made "a powerful plea for early implementation" [S1].
• The Minister described the takeover question as "complex," signalling government hesitation despite committee recommendations [S1].
• Contemporary resonance (2024–26): India's debate over MNC acquisitions of domestic pharma firms (e.g., post-Ranbaxy, Sun Pharma era) and the Essential Medicines affordability agenda echo the same 1970s concerns; The Hindu republished this archival piece in January 2026 to contextualise ongoing policy debates [S1].

3. Background & Evolution

4. Core Static Facts

The Hathi Committee

• Full name: Committee on Drugs & Pharmaceutical Industry
• Chairperson: Justice Jaisukhlal Hathi (retired Supreme Court judge)
• Year constituted: 1974; report submitted: 1975
• Nodal Ministry: Ministry of Chemicals & Fertilizers (then Ministry of Chemical and Fertilizers) [S1]
• Minister who replied in Lok Sabha (1976): P.C. Sethi [S1]
• Key parliamentarians who raised the debate: CPI's Ramavatar Shastri and Hiren Mukherjee [S1]

Key Recommendations of Hathi Committee

• Takeover/nationalisation of MNC pharmaceutical companies operating in India.
• Public sector to control at least 50% of bulk drug production.
• Strict price controls on essential medicines.
• Promotion of indigenous R&D to reduce technology dependence.
• Rationalisation of drug formulations — eliminate irrational combinations.

Enabling Legal/Policy Context

• Patents Act, 1970 — process-patent-only regime (predated report; created conditions for domestic generics).
• Drugs & Cosmetics Act, 1940 — regulatory backbone for drug standards.
• Essential Commodities Act — mechanism for price control.
• New Drug Policy, 1978 — partial implementation vehicle post-Hathi report.
• DPCO (Drug Price Control Order) — first issued 1970; revised 1979, 1987, 1995, 2013.

5. Multi-Dimensional Analysis

Economic

• MNCs controlled a disproportionate share of formulation sales in India in the 1970s; bulk drug import dependence made medicines costly [S2].
• Hathi report argued that transfer pricing by MNCs inflated costs and drained foreign exchange — a classic MNC-host country conflict.
• Takeover debate reflected broader import-substitution industrialisation (ISI) philosophy dominant in 1970s India.
• Partial implementation through the 1978 Drug Policy helped catalyse India's domestic generics industry, eventually making India the "pharmacy of the world" (supplying ~20% of global generic medicines by volume) [S2].

Geopolitical / Strategic

• Cold War context: CPI members pushing for nationalisation aligned with socialist bloc influence; government's cautious "under consideration" stance reflected balance-of-payments concerns and Western investment diplomacy [S1].
• Technology dependence on MNCs for Active Pharmaceutical Ingredients (APIs) was a national security concern.
• Post-COVID-19 (2020–26), the same strategic logic drives PLI (Production-Linked Incentive) Scheme for Pharmaceuticals (₹15,000 crore, 2021) to boost domestic API and key starting material (KSM) production.

Legal / Constitutional

• No constitutional provision directly mandates socialisation of industry; Article 39(b) (DPSP) — material resources of the community should be distributed to serve common good — was cited as philosophical basis for takeover proposals.
• Article 19(1)(g) (right to trade/profession) and property rights created constitutional constraints on nationalisation without fair compensation.
• SC ruling in Ranganatha Reddy (1977) and later Sanjeev Coke (1983) upheld nationalisation laws under DPSP override.

Scientific / Technological

• MNCs held proprietary process and (pre-1970) product patents; Hathi report identified this as the root cause of technology lock-in.
• Process patent regime (Patents Act, 1970) had already broken the MNC monopoly — Hathi recommendations built on this to argue for full public sector control.
• Takeover was seen as a route to technology transfer to Indian public sector labs (e.g., Hindustan Antibiotics Ltd, IDPL).

Ethical / Governance

• Core ethical tension: access vs. innovation — MNCs argued takeover would deter future R&D investment; public health advocates argued profits were prioritised over essential medicine availability.
• Hathi report itself noted irrational drug formulations and high-margin "branded" medicines as ethical failures of the MNC-dominated market.
• The debate raised questions of parliamentary accountability — committee report recommendations vs. executive delay ("under consideration" for years) [S1].

Administrative

• Key bottleneck: absence of technical capacity in public sector to absorb taken-over MNC facilities.
• Central vs. State jurisdiction issue: drug manufacturing licensing (State); pricing and import control (Central).
• Implementation gap: successive governments (1975–85) cited "complexity" to defer full Hathi implementation — classic policy inertia.

6. Recent Developments (last 12–18 months)

• 2025–26: The Hindu's republication (Jan 2026) of this 1976 article signals renewed editorial interest in the historical roots of India's pharma sovereignty debate [S1].
• PLI Scheme for Pharmaceuticals (approved 2021, implementation ongoing 2024–26): ₹15,000 crore incentive to reduce API import dependence from China — a structural echo of Hathi's domestic self-reliance agenda.
• Jan Aushadhi Scheme (Pradhan Mantri Bhartiya Janaushadhi Pariyojana): 14,000+ stores by 2025 selling generic medicines at 50–90% below branded prices — operational embodiment of Hathi's access goals.
• FDI in pharma greenfield (100% automatic) vs. brownfield (74% automatic; above 74% via approval route) — government's calibrated position on MNC entry, following 2011 Parliamentary Committee recommendations on restricting takeovers.
• WHO Global Medicines Shortage discourse (2024–25) reinvigorated arguments for national pharmaceutical self-sufficiency in member states [S3].

7. Prelims Hooks

1. The Hathi Committee was formally called the Committee on Drugs & Pharmaceutical Industry, constituted in 1974.
2. It was chaired by Justice Jaisukhlal Hathi, a retired Supreme Court judge — not a minister or bureaucrat.
3. The nodal ministry was Ministry of Chemical and Fertilizers (today: Ministry of Chemicals & Fertilizers) [S1].
4. The minister who replied to the Lok Sabha debate (Jan 22, 1976) was P.C. Sethi [S1].
5. CPI members Ramavatar Shastri and Hiren Mukherjee initiated the Lok Sabha discussion on the Hathi report [S1].
6. The government's stated position in 1976 was that takeover was "under the consideration of the Government" — neither approved nor rejected [S1].
7. The Patents Act, 1970 abolished product patents for drugs and foods; only process patents (7 years) were allowed — a pre-condition that enabled the Hathi recommendations.
8. The New Drug Policy, 1978 partially implemented Hathi Committee recommendations — introduced drug price controls and MNC equity caps.
9. Drug Price Control Order (DPCO), 1979 was the first major pricing order flowing from post-Hathi policy reform.
10. Under TRIPS (1995), India had a transition period until 2005 to restore product patent protection for pharmaceuticals.
11. The Patents (Amendment) Act, 2005 reintroduced product patents in India, marking a reversal of the 1970 regime that underpinned Hathi's recommendations.
12. Article 39(b) of the Constitution (DPSP) — distribution of material resources for common good — provides constitutional philosophy underpinning nationalisation proposals.
13. India's PLI Scheme for Pharmaceuticals (2021): outlay of ₹15,000 crore — a modern policy parallel to Hathi's self-reliance objective.

8. Mains Relevance

Plausible Mains Questions: 1. "The Hathi Committee report of 1975 reflected the tensions inherent in India's development model. Critically examine its recommendations and their long-term impact on the Indian pharmaceutical industry." (GS-III, 15M) 2. "Access to affordable medicines remains a challenge in India despite decades of policy intervention. Trace the evolution of India's drug pricing policy from the Hathi Committee to the DPCO 2013." (GS-III, 15M) 3. "Parliamentary committee reports often serve as blueprints for reform but face significant implementation gaps. Illustrate with reference to the Hathi Committee and any one other example." (GS-II, 10M)

9. Related Topics to Study Next

10. Common Errors / Trap Areas

1. Wrong decade: Aspirants confuse the Hathi Committee (1974–75) with the Drug Policy Committee (1986) or the Mashelkar Committee (2003) on patent law — these are three distinct bodies with different mandates.
2. Wrong ministry: The committee reported to Ministry of Chemical and Fertilizers — not the Ministry of Health & Family Welfare, though Health Ministry was consulted.
3. Nationalisation ≠ implementation: The Hathi Committee recommended takeover; the government never fully nationalised MNC pharma firms. Only partial measures (price controls, equity caps) were taken via the 1978 Drug Policy. Examiners test whether aspirants know the gap between recommendation and action.
4. Patents Act, 1970 confusion: The 1970 Act abolished product patents for drugs — it did not abolish patents entirely. Process patents (7 years for drugs) were retained. Confusing this with the 2005 Amendment (which restored product patents) is a common slip.
5. CPI vs. Congress position: The Hathi debate saw CPI members (opposition) push hardest for nationalisation while the ruling Congress government took a cautious "under consideration" stance [S1] — aspirants sometimes invert this.

11. Sources

• [S1] "Centre studying take-over of foreign drug firms" — The Hindu print archive, New Delhi, Jan. 22 (published Jan. 23), 1976; republished/accessed via thehindu.com — (Tier 4). (Primary source: article content supplied in prompt)
• [S2] "Indian Pharmaceutical sector — PIB Blog" — https://blogs.pib.gov.in/blogsdescr.aspx?feaaid=68 — (Tier 1)
• [S3] WHO medicines and health products page — who.int (general contextual reference; domain whitelisted Tier 2)
• [S4] Business Standard — "Seven of top 10 drug brands sold in India are from multinational companies" — https://www.business-standard.com/article/companies/7-of-top-10-drug-brands-sold-in-india-are-from-multinational-companies-119102101293_1.html — (Tier 4)

Examiner's Note: This topic is tested as a historical policy case study rather than a live scheme. The most testable facts are the committee name, chair, year, nodal ministry, the 1976 Lok Sabha exchange, and the link to the Patents Act 1970 and New Drug Policy 1978. Do not confuse it with contemporary FDI pharma debates — though those debates are the legacy of Hathi's unfinished agenda.